{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265"}]}],"title":"AEs : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"102"}]}],"title":"AEs : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"127"}]}],"title":"Treatment-related AEs : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"Treatment-related AEs : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"91"}]}],"title":"SAEs : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}],"title":"SAEs : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Fatal SAEs : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Fatal SAEs : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment-related fatal SAEs : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment-related fatal SAEs : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"AEs leading to discontinuation : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"AEs leading to discontinuation : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Treatment-related AEs leading to discontinuation : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Treatment-related AEs leading to discontinuation : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"title":"AEs leading to dose adjustment/interruption : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"AEs leading to dose adjustment/interruption : Grades ≥3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"220"}]}],"title":"AEs requiring additional therapy : All grades"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"}]}],"title":"AEs requiring additional therapy : Grades ≥3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"}],"units":"Participants"}],"description":"Collect long term safety data, i.e. SAEs and AEs. SAES will be reviewed and reported as part of the regular pharmacovigilance activities.","groups":[{"description":"Patients who were treated with and had benefitted from pasireotide in the parent studies remained enrolled in this study and were elegible for the analysis","id":"OG000","title":"All Subjects"}],"paramType":"NUMBER","populationDescription":"The Safety Set included all patients who received at least one dose of study medication (pasireotide) after enrolling into the roll-over protocol","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 10 years","title":"Incidence of Adverse Events to Evaluate Long Term Safety Data","type":"PRIMARY","unitOfMeasure":"participants"}